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Objectives This study sought to evaluate 30-day all-cause mortality of patients treated with primary
percutaneous coronary intervention (PCI) presenting with an acute myocardial infarction (AMI) due
to an unprotected left main coronary artery (ULMCA) culprit lesion. In addition, an average esti-
mated mortality rate was extrapolated from the available data.
Background There are limited data available on clinical outcome after primary PCI in patients pre-
senting with AMI with unprotected left main as the infarct-related coronary artery.
Methods Medical literature databases were searched to identify cohort studies reporting on primary
PCI for unprotected left main–related AMI. A total of 13 retrospective studies meeting all pre-speci-
ﬁed criteria were included in the meta-analysis. No randomized trials were available. The primary
endpoint for the meta-analysis was 30-day all-cause mortality.
Results This meta-analysis comprises a total of 977 patients, of which 252 (26%) presented in cardi-
ogenic shock. Thirty-day all-cause mortality was evaluated using a forest plot analysis and showed
higher event rates in patients presenting with cardiogenic shock among all subgroups. The average
estimated 30-day all-cause mortality was 15% in patients presenting without signs of cardiogenic
shock and 55% in patients presenting with cardiogenic shock (relative risk: 3.74, 95% conﬁdence
interval [CI]: 2.95 to 4.76, p  0.001).
onclusions In this large meta-analysis of patients treated with primary PCI for AMI due to an
LMCA culprit lesion, the 30-day all-cause mortality in patients presenting with shock is much
igher than in patients not presenting with shock. The estimated all-cause mortality data may serve
s a benchmark for future reference. (J Am Coll Cardiol Intv 2013;6:317–24) © 2013 by the
merican College of Cardiology FoundationA significant involvement of the left main coronary
artery occurs in 4% to 7% of patients presenting
with an acute myocardial infarction (AMI) (1,2).
From the Department of Cardiology, Academic Medical Center, Am-
sterdam, the Netherlands. Prof. Dr. Piek is on the medical advisory board
f Abbott Vascular; and is a consultant for Miracor. All other authors have
eported that they have no relationships relevant to the contents of this paper
o disclose. The first two authors contributed equally to this work.anuscript received May 14, 2012; revised manuscript received Septem-
er 4, 2012, accepted October 11, 2012.These critically ill patients frequently present with
cardiogenic shock or cardiac arrest and are at high
risk for in-hospital major cardiac adverse events
(3,4). In nonurgent patients, coronary artery bypass
grafting (CABG) has been the standard treatment
for significant unprotected left main coronary ar-
tery (ULMCA) stenosis and is recommended as
first choice of treatment by the American College
of Cardiology/American Heart Association (5) and
European Society of Cardiology (6) guidelines. In
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318selected patients, however, several studies have reported increas-
ingly good immediate and 1-year outcomes of ULMCA stenting
comparable to the outcomes reported after CABG (7–11).
Long-term follow-up of the SYNTAX (SYNergy Between
PCI With TAXUS and Cardiac Surgery) trial showed that
overall major adverse cardiac and cerebrovascular event rates
were not significantly different between the percutaneous
coronary intervention (PCI) group compared with the CABG
group in the pre-specified left main coronary artery subgroup at
3 years (12). Although more PCI patients required reinterven-
tion, less stroke was observed compared with CABG-treated
patients.
In patients presenting with AMI, primary PCI is consid-
ered the optimal reperfusion strategy (13). Whether PCI is
the preferred therapy for significant involvement of ULMCA is
still subject to debate. At present, the American Heart Association
and American College of Cardiol-
ogy guidelines are less clear about
the optimal standard of care for
patients presenting with an AMI
due to a ULMCA culprit lesion
(14). However, it is generally ac-
cepted to perform PCI in high-risk
patients, such as patients in cardio-
genic shock or cardiac arrest where
CABG is associated with too high a
mortality risk. Currently, there are
only limited data on immediate per-
cutaneous treatment for patients
with an AMI due to a ULMCA
culprit lesion. Especially for those
complicated by cardiogenic shock,
the left main shock syndrome, only
small cohorts have been described.
We therefore performed a
systematic review on the cur-
rently available literature and a
meta-analysis on the treatment
of PCI for an AMI due to a ULMCA culprit lesion.
Patients were categorized according to initial clinical pre-
sentation of AMI with or without cardiogenic shock. Our
second goal was to calculate an average mortality rate for
this patient category from the available data, which may
serve as a benchmark for future studies in this very high-risk
patient group.
Methods
Inclusion criteria for the meta-analyses. To date, there are
o randomized trials concerning primary PCI for left main
oronary artery AMI. We therefore only included outcome
Abbreviations
and Acronyms
AMC  Academic Medical
Center
AMI  acute myocardial
infarction
BA  balloon angioplasty
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
PCI  percutaneous
coronary intervention
RR  relative risk
STEMI  ST-segment
elevation myocardial
infarction
ULMCA  unprotected left
main coronary arteryata from cohort studies describing: d1. patients undergoing primary PCI for an AMI due to a
ULMCA culprit lesion;
2. patients with reported 30-day all-cause mortality and;
3. a clear description of whether patients presented with or
without cardiogenic shock and/or pre-procedure cardiac
arrest with successful cardiopulmonary resuscitation.
Cardiogenic shock or pre-procedure cardiac arrest with
uccessful cardiopulmonary resuscitation hereinafter is re-
erred to as cardiogenic shock. All studies required that
ither in-hospital or 30-day mortality was available for at
east 90% of the patients. In-hospital or 30-day mortality
ereinafter is referred to as 30-day all-cause mortality.
Data source. We performed a MEDLINE (PubMed) lit-
rature search up to August 2011 for cohort studies describ-
ng the 30-day outcomes after primary PCI for unprotected
eft main AMI. Searches included the key words and
orresponding Medical Subject Headings (MeSH) for un-
rotected left main coronary artery disease and AMI. All
otentially relevant articles were independently reviewed by
investigators (M.M.V. and M.A.B.) to establish eligibility
or the meta-analysis. In case of disagreement, this was
esolved in consultation with a third reviewer (J.P.S.H.).
itations were screened at title/abstract level and retrieved
s full reports. Non-English articles, case reports, and
lective or non-urgent interventions were excluded.
The flow chart of the search strategy and selection of
tudies is depicted in Figure 1. We identified 21 nonran-
omized cohort studies for inclusion in our meta-analysis.
ight studies were excluded because 30-day outcomes were
nly reported for the total study population and did not
iscriminate between patients with and without cardiogenic
hock. One study was excluded because all patients with left
ain coronary AMI were treated with CABG. Finally, we
ncluded the results from a comparative cohort study of
rimary PCI for an AMI due to a ULMCA culprit lesion
rom our own research group (the Academic Medical
enter [AMC] cohort). Therefore, a total of 13 cohort
tudies were included in our meta-analysis of primary PCI
or an AMI due to a ULMCA culprit lesion (Table 1).
Data extraction and deﬁnitions. Pre-specified patient char-
cteristics, the outcome, and the completeness of the
ollow-up data were independently extracted by 2 investi-
ators (M.M.V. and M.A.B.). Data were grouped for
ardiogenic shock at presentation and primary PCI. PCI
reatment was clustered between balloon angioplasty (BA)
nd/or bare-metal stent (BMS), BMS and/or drug-eluting
tent (DES), or DES alone.
Unprotected left main was considered to be angiographi-
ally documented stenosis 50% located in the left main
oronary artery with no patent graft to the left anterior
escending or circumflex coronary artery (15). AMI was
efined as clinical and/or electrocardiographic signs of an
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319AMI according to the universal definition of AMI (16). In
addition, all patients underwent PCI for the left main after
angiography. Cardiogenic shock was described in each
individual study and was generally defined as systolic blood
pressure 90 mm Hg for at least 30 min or the need for
supportive measures to maintain a systolic blood pressure
above 90 mm Hg and/or the clinical signs associated with
end-organ hypoperfusion, such as cool extremities (or a
urine output of 30 ml/h, and a heart rate of 60
beats/min) and/or patients presenting with a pre-
procedure cardiac arrest with successful cardiopulmonary
resuscitation (17).
Data synthesis and analysis. The primary endpoint for the
meta-analysis was 30-day all-cause mortality. Results are
presented as risk ratios for binary outcome measures with
95% confidence intervals (CIs). Binary outcomes from
individual studies were combined respectively, with the
random-effect models. We examined heterogeneity across
studies by the Cochran’s Q statistic and the I2 statistic.
otential publication bias was assessed by visual assessment
f constructed funnel plots. Average estimated 30-day
ll-cause mortality of patients undergoing primary PCI for
n AMI due to a ULMCA culprit lesion were calculated as
elative risks (RR). Tests were 2-tailed, and a p value of 0.05
as considered statistically significant. Review Manager
RevMan version 5.1, Nordic Cochrane Centre, Cochrane
ollaboration, Copenhagen, Denmark) was used for statis-
Figure 1. Flow Chart of Search Strategy
Flow chart demonstrating the search strategy and selection of eligible studies
bypass grafting; PCI  percutaneous coronary intervention.ical analysis.esults
Characteristics of the studies included in the meta-
analysis. Searches included the key words and correspond-
ing Medical Subject Headings (MeSH) unprotected left
main disease and acute myocardial infarction. We found
406 studies on unprotected left main disease. After entering
the second key word, 188 articles remained. After title
screening, only 124 studies were selected for further evalu-
ation. A total of 114 articles remained upon excluding
non-English articles, case reports, elective or non-urgent
interventions. These studies were screened for data on
mortality and documentation and presence of cardiogenic
shock. Finally, 13 studies (18–29), including our AMC
cohort, met all criteria and were included in this meta-
analysis (Fig. 1). The funnel plot shows a skewed distribu-
tion suggesting publication bias was present. Study charac-
teristics are shown in Table 1. All but 3 were single-center
registries. All PCIs were performed between 1990 and
2010. Of the 12 studies, only 3 studies included pre-
procedure cardiac arrest patients with successful cardiopul-
monary resuscitation: Bonello et al. (19) included 4 cardiac
arrest patients, Yip et al. (29) included 6 cardiac arrest
patients, Pedrazzini et al. (25) included 37 cardiac arrest
patients. In our cohort, 15 patients with pre-procedure
cardiac arrest with successful cardiopulmonary resuscitation
were included, resulting in a total of 62 of 977 patients
(6.3%). Patients with pre-procedure cardiac arrest with
e meta-analysis. AMC  Academic Medical Center; CABG  coronary arteryfor thsuccessful cardiopulmonary resuscitation and PCI per-
Table 1. Characteristics of Cohort Studies Analysis on Primary PCI of a ULMCA Culprit Lesion in the Setting of AMI
First Author (Ref. #) Patients (N) Setting Period Type of PCI Cardiogenic Shock Definition Age (Yrs, Mean  SD) Men (%) Angiographic Finding
Yip et al. (29) 18 Single center 1993–2000 BA/BMS NA 67 12 NA 4 pts 1VD, 9 pts 2VD,
2 pts 3VD
De Luca et al. (20) 24 Single center 1990–2001 BA/BMS NA 61 13 88 12 pts 3VD
Lee et al. (23) 18 Single center 1997–2002 BMS NA 59 12 89 13 pts multivessel disease
Valeur et al. (28) 12 Single center 2000–2003 BA/BMS Persistent arterial hypotension (systolic blood pressure
80 mm Hg).
65 (IQR: 33–83) 67 4 pts 3VD
Hurtado et al. (21) 42 Single center 1999–2007 BMS/DES Systolic blood pressure 90 mm Hg with signs of
hypoperfusion or need for vasoactive drugs or IABC
to maintain blood pressure.
67 13 82 NA
Bonello et al. (19) 13 Single center 2005–2006 BMS/DES NA 72 10 54 12 pts multivessel disease
Montalescot et al. (24) 318 Multicenter 2000–2007 BMS/DES NA NA NA NA
Jensen et al. (22) 71 Multicenter 2005–2007 BMS/DES NA 69 11 70 75% LM stenting only,
25% bifurcation
stenting
Pepe et al. (26) 22 Single center 2002–2006 BMS/DES Systolic blood pressure 90 mm Hg (without
inotropic drugs or intra-aortic balloon support) that
was unresponsive to intravenous ﬂuid
administration, secondary to cardiac dysfunction,
and associated with signs of hypoperfusion
dysfunction, and associated with signs of
hypoperfusion (cold extremities, impaired mental
status, or urine output 30 ml/h).
72 12 NA NA
Pedrazzini et al. (25) 348 Multicenter 2005–2010 BMS/DES NA 64 13 75 217 pts isolated LM,
9 pts 1VD, 63 pts 2VD,
59 pts 3VD
Barlis et al. (18) 20 Single center 2003–2005 DES Systolic blood pressure 90 mm Hg for 30 min or
the need for supportive measures to maintain a
systolic blood pressure 90 mm Hg and end-organ
hypoperfusion (cool extremities or a urine output
of 30 ml/h, and a heart rate of 60 beats/min).
pts in cardiogenic shock:70
(IQR: 55–79); pts not in
shock: 69 (IQR: 44–91)
80 vs. 67 NA
Tan et al. (27) 16 Single center 2003–2005 DES NA Alive 62  12; dead 61  11 81 9 pts isolated LM, 7 pts
multivessel disease
AMC cohort (this study) 55 Single center 1998–2008 BA/BMS/DES Systolic blood pressure 90 mm Hg for at least
30 min or the need for supportive measures to
maintain a systolic blood pressure above
90 mm Hg and end-organ hypoperfusion (e.g.,
urine output 30 ml or cold, diaphoretic extremities
or altered mental status) or patients presenting
with a cardiac arrest.
64 12 75 20 pts isolated LM,
15 pts 1VD, 11 pts
2VD, 9 pts 3VD
AMCAcademicMedical Center; AMI acutemyocardial infarction; BAballoon angioplasty; BMSbare-metal stent(s); DESdrug-eluting stent(s); NAnot available; IABC intra-aortic balloon counterpulsation; IQR interquartile range; LM leftmain coronary
artery; PCI percutaneous coronary intervention; pt patient; ULMCA unprotected left main coronary artery; VD vessel disease.
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321formed were considered patients presenting with cardio-
genic shock.
Clinical outcomes. This meta-analysis comprises 977 pa-
tients. A total of 252 (26%) patients presented with cardi-
ogenic shock. The observed 30-day all-cause mortality was
57% among patients presenting with cardiogenic shock and
11% among those without cardiogenic shock (risk ratio:
3.15, 95% CI: 1.90 to 5.23). A forest plot was performed
from all individual studies presenting with 30-day all-cause
mortality of patients with cardiogenic shock and patients
without cardiogenic shock (Fig. 2). In 4 cohorts (N  72,
7.4% of all patients), BA and/or bare-metal stenting was
performed; in 7 cohorts (N  869, 89% of all patients),
ncluding our AMC cohort, BMS and/or DES were used;
nd in 2 cohorts (N  36, 3.7% of all patients), only DES
ere implanted (Fig. 2). In the BA and/or BMS subgroups,
he observed 30-day all-cause mortality was 59% among
atients admitted with cardiogenic shock and 21% among
atients without cardiogenic shock (risk ratio 2.09, 95% CI:
.81 to 5.42). In the BMS or DES subgroup, the observed
0-day all-cause mortality was 56% among patients with
ardiogenic shock and 11% among patients without cardi-
genic shock (risk ratio: 3.19, 95% CI: 1.70 to 5.97). In the
Figure 2. Forrest Plot
Forrest plot showing risk ratios for 30-day all-cause mortality in patients with a
BA  balloon angioplasty; BMS  bare-metal stent(s); CI  conﬁdence interva
nary intervention.ES subgroup, the observed 30-day all-cause mortality was
3% among patients with cardiogenic shock, whereas no
atients died within 30 days when they presented without
ardiogenic shock (risk ratio: 11.60, 95% CI: 1.66 to 80.97).
n the BA and/or BMS groups and the DES group, there
as no evidence of heterogeneity across the different trials.
n the BMS and/or DES group, however, there was
eterogeneity observed between the trials. Overall, there
as a statistically significant heterogeneity across the 13
tudies (I2  62%).
Average estimated 30-day all-cause mortality. Thirty day
all-cause mortality of patients among the different studies
and the weight factor per study is shown in Table 2. The
calculated average estimated 30-day all-cause mortality was
15% in patients without cardiogenic shock and 55% in
patients with cardiogenic shock (RR: 3.74, 95% CI: 2.95 to
4.76, p  0.001) (Table 3). A similar trend was seen in all
ubgroups (Table 3).
iscussion
This is the first meta-analysis on primary PCI for an AMI
due to a ULMCA culprit lesion with and without cardio-
ithout presentation with cardiogenic shock, stratiﬁed by PCI type.
 drug-eluting stent(s); M-H  Mantel-Haenszel; PCI  percutaneous coro-nd w
l; DES
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322genic shock. Our main findings are that patients undergoing
primary PCI for an AMI due to a ULMCA culprit lesion
and presenting with cardiogenic shock have a high 30-day
mortality compared with patients without cardiogenic
shock, regardless of stent type. In addition, we calculated an
average estimated 30-day all-cause mortality in patients
with and without cardiogenic shock that may serve as a
benchmark for future studies.
Primary PCI for an AMI due to a ULMCA culprit lesion
is a rare procedure, frequently associated with adverse
clinical outcomes. The incidence of AMI due to a ULMCA
culprit lesion is reported to be 0.8% to 5.4% (30). Given the
infrequent nature of this left main syndrome, our meta-
analysis aimed to review the available data in literature. As
expected, a large proportion of patients in this meta-analysis
presented with cardiogenic shock (26%). It is likely that the
average incidence of this left main syndrome may in fact be
higher due to the various clinical conditions and medical
decision making in a patient population with an expected
very poor outcome. This meta-analysis provides a bench-
mark for clinical outcome in patients presenting with an
AMI due to a ULMCA culprit lesion, which may serve for
comparison, especially when patients are presenting with an
already high risk for adverse clinical events, and for multiple
Table 2. 30-Day All-Cause Mortality of Patients Amo
First Author (Ref. #) Cardiogenic Shock (%)
Yip et al. (29) 43 (6/14)
De Luca et al. (20) 80 (12/15)
Lee et al. (23) 43 (6/14)
Valeur et al. (28) 70 (7/10)
Hurtado et al. (21) 57 (16/28)
Bonello et al. (19) 44 (4/9)
Montalescot et al. (24) 40 (10/25)
Jensen et al. (22) 55 (16/29)
Pepe et al. (26) 31 (4/13)
Pedrazzini et al. (25) 55 (23/42)
AMC cohort (this study) 78 (29/37)
Barlis et al. (18) 60 (3/5)
Tan et al. (27) 64 (7/11)
Values are % (n/N).
AMC Academic Medical Center.
Table 3. Average Estimated 30-Day All-Cause Mortality
Group
No Cardiogenic
Shock
Cardiogenic
Shock RR 95% CI p Value
BA and/or BMS 20.8 61.7 2.97 1.46–6.06 0.003
BMS and/or DES 14.7 53.1 3.60 2.79–4.65 0.0001
DES 0 61.7 — — —
Overall 15.0 55.0 3.74 2.95–4.76 0.0001
Values are %.CI confidence interval; RR relative risk; other abbreviations as in Table 1.reasons, physicians may refrain from taking these patients to
the catheterization laboratory and further therapy. A strik-
ing difference in mortality was observed between the studies
included in our meta-analysis. This may be partly explained
by differences in definition of shock and patient selection. A
trend towards higher mortality over time was observed,
perhaps related to the widespread acceptance of primary
PCI for more complex patients. In our center, primary PCI
has evolved as the standard of care, and all ST-segment
elevation myocardial infarction (STEMI) patients within
our geographic referral area with or without cardiogenic
shock, are transferred for primary PCI. This may explain the
relatively high number of patients in our cohort, treated in
critically ill conditions, such as cardiogenic shock or cardiac
arrest. It is noteworthy that this meta-analysis showed that
in patients not in cardiogenic shock who received a DES
showed no mortality at 30 days; however, due to the small
number of patients, future studies will have to confirm this
finding.
In this meta-analysis, the use of balloon angioplasty,
BMS or DES revealed similar clinical outcomes in patients
presenting with cardiogenic shock. In patients without
cardiogenic shock, treatment with DES seem to be associ-
ated with an improved 30-day all-cause mortality. However,
this may be related to the time period the study was
performed because the BA/BMS subgroup studies all in-
cluded patients before 2004. Over the last years, practice has
changed with improved PCI techniques, assist devices, use
of thrombosuction devices, and antiplatelet therapy or
additional medication. A hybrid approach of initial revas-
cularization by primary PCI and elective surgery afterwards
remains an alternative treatment option. Treating patients
with cardiogenic shock or after cardiac arrest is one of the
most challenging PCI procedures due to the nature of the
Different Studies
No Cardiogenic Shock (%) Weight Factor
0 (0/4) 2.43
22 (2/9) 4.40
50 (2/4) 2.43
0 (0/2) 1.30
29 (4/14) 7.30
0 (0/4) 2.16
13 (38/293) 18.01
14 (6/42) 13.41
33 (3/9) 4.16
5 (15/306) 28.87
33 (6/18) 9.90
0 (0/15) 2.93
0 (0/5) 2.69ng theclinical presentation while targeting a coronary lesion asso-
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323ciated with a very large area of the myocardium at risk.
These hemodynamically unstable patients have an extensive
amount of ischemic myocardium. Compensatory systemic
inflammatory stress syndrome and redistribution of blood
from the vital organs can lead to multiorgan failure (31).
Immediate mechanical hemodynamic support may prevent
from further multiorgan failure. The recent CRISP AMI
(Counterpulsation to Reduce Infarct Size Pre-PCI Acute
Myocardial Infarction) trial did not show a beneficial effect
of intra-aortic balloon pumping before PCI for STEMI in
non-cardiogenic shock patients (32). However, the ongoing
ISAR SHOCK 2 (Efficacy Study of LV Assist Device to
Treat Patients With Cardiogenic Shock) trial will ulti-
mately shed light on the effects of intra-aortic balloon
pumping in STEMI patients presenting with cardiogenic
shock and treated with PCI (33). Whether newer and more
powerful circulatory assist devices (Impella/TandemHeart/
ECMO) will result in better outcomes is the subject of
ongoing clinical evaluation before widespread adoption (34).
This meta-analysis of primary PCI for AMI due to a
ULMCA culprit lesion provides a benchmark that may
serve for future reference, to optimize treatment of this
high-risk patient group with, for example, left ventricular
assist devices or hybrid revascularization.
Study limitations. All studies included in this meta-analysis
re retrospective, reflecting outcomes after clinical decision
aking by treating physicians, including taking patients to
he catheterization laboratory in very poor condition and the
sage of different modes of PCI (BA and different types of
ntracoronary stents) as well as different types of hemody-
amic support devices. In addition, these data are also
ampered by clinical decision making in patients that
ndergo CABG after immediate coronary angiography, as
hey only describe patients that actually underwent PCI.
oreover, selection bias based on the time differences
etween CABG or PCI is inevitable. From the studies
ncluded in this meta-analysis, no discrimination could be
ade between patient groups treated solely with BA, BMS,
r DES. Detailed descriptions of cause of death were not
vailable, specifically for patients with pre-procedure cardiac
rrest with successful cardiopulmonary resuscitation, be-
ause those patients might have a worse outcome. There-
ore, the primary endpoint of this meta-analysis was 30-day
ll-cause mortality. Finally, in 4 of the 13 studies included,
he angiographic data on the severity of coronary artery
isease were not available.
onclusions
This is the first meta-analysis, to our knowledge, on primary
PCI for AMI due to a ULMCA culprit lesion. The
observed 30-day all-cause mortality rate was higher in
patients presenting with cardiogenic shock compared with
patients without cardiogenic shock. The results were notaffected by stent type. In addition, for benchmark purposes,
we calculated an average estimated 30-day all-cause mor-
tality of 55% for patients with cardiogenic shock and 15%
for patients without cardiogenic shock. Table 2
Reprint requests and correspondence: Dr. José P. S. Henriques,
Department of Cardiology, Academic Medical Center, University
of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Neth-
erlands. E-mail: j.p.henriques@amc.uva.nl.
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